Comparative Pharmacology
Head-to-head clinical analysis: MD 76R versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76R versus RENOVIST.
MD-76R vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal half-life 1-2 hours; prolonged in renal impairment.
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent